Novartis AG Stock Price Targets

Comprehensive analysis of short, mid, and long-term price targets for Novartis AG (NVS).

Back to Analysis Hub

Give me a comprehensive price target analysis for Novartis AG (NVS).

Below is a comprehensive, data-driven analysis for Novartis AG (NVS) as of 2025-10-10, with three horizontal price-target lines drawn (Low, Median, High) and a detailed price-target framework anchored to forward earnings and valuation.

Notes on price-target lines drawn (Price Targets: Low/Median/High)

  • Low Target: 120
  • Median Target: 145
  • High Target: 165
  • These lines were drawn on the price chart and extended 30 days into the future from today (2025-10-10) to 2025-11-09.
  • Rationale (derived, not analyst consensus):
    • Low Target (120): modest downside scenario driven by potential multiple compression or near-term market jitters.
    • Median Target (145): base-case aligned with forward P/E dynamics and consensus-like growth assumptions.
    • High Target (165): bull-case assuming solid earnings growth, favorable pipeline progress, and multiple expansion.
  • Visual reference: The colors used for the lines are red (Low), blue (Median), and green (High).

Executive Summary

  • NVS remains a high-quality, cash-generative pharma with solid margins, a strong ROE, and a conservative balance sheet. The stock currently trades around 131 USD with a forward P/E near 15.6x, signaling modest valuation support given earnings growth and cash generation.
  • The near-term technical setup shows positive momentum: price sits above the 50-day moving average, and MACD remains bullish, though RSI at recent highs (~74–75) warns of potential short-term pullbacks if momentum wanes.
  • The earnings trajectory (recent quarters) shows sustained profitability with improving normalized earnings, supporting a constructive longer-term view. EPS revisions have been modestly net-positive in recent periods.
  • Our price-target framework (short/mid/long) suggests upside potential versus today’s price, with a base case around mid-140s and bull-case near 165, contingent on earnings momentum and pipeline progress.

Fundamental Analysis (Key Valuation & Health Metrics)

  • Price (current): 131.06 USD
  • Market Cap: 255.67B
  • Enterprise Value: 282.11B
  • Valuation Multiples:
    • Trailing P/E: 19.13x
    • Forward P/E: 15.57x
    • Price to Book: 6.04x
  • Profitability & Efficiency:
    • Return on Equity (ROE): 32.49%
    • Return on Assets (ROA): 11.88%
    • Gross Margin: 76.28%
    • Operating Margin: 36.83%
    • Net Profit Margin: 24.74%
  • Balance Sheet & Leverage:
    • Total Cash: 6.73B
    • Total Debt: 32.64B
    • Debt to Equity: 77.61
  • Cash Flow & Dividends:
    • Dividend Yield: 3.02% (versus five-year avg 3.61%)
  • Growth & Quality:
    • Five-year average dividend yield: 3.61% (current yield slightly below historical average)
    • Beta: 0.57 (defensive bias; relatively low market volatility)
  • Takeaway: The stock sits at a reasonable forward earnings multiple given robust profitability and a strong balance sheet, albeit with a meaningful debt load by pharma standards and a conservative dividend yield relative to the peak of the last cycle.

Earnings Analysis Recent Earnings Summary (Key figures from the provided data)

  • 2025-06-30:
    • Normalized Income: 4.041B
    • Net Income: 4.041B
    • Diluted EPS: 2.06
    • Basic EPS: 2.07
    • EBITDA: 6.076B
    • EBIT: 4.820B
    • Total Revenue: 14.836B
  • 2025-03-31:
    • Normalized Income: 3.601B
    • Net Income: 3.606B
    • Diluted EPS: 1.82
    • Basic EPS: 1.83
    • EBITDA: 5.831B
    • EBIT: 4.670B
    • Total Revenue: 13.620B
  • 2024-12-31:
    • Normalized Income: 2.818B
    • Net Income: 2.818B
    • Diluted EPS: 1.41
    • Basic EPS: 1.42
    • EBITDA: 5.188B
    • EBIT: 3.560B
    • Total Revenue: 13.558B
  • 2024-09-30:
    • Normalized Income: 3.184B
    • Net Income: 3.189B
    • Diluted EPS: 1.57
    • Basic EPS: 1.58
    • EBITDA: 5.614B
    • EBIT: 3.649B
    • Total Revenue: 13.172B
  • 2024-06-30:
    • Normalized Income: 5.249B
    • Net Income: 3.246B
    • Diluted EPS: 1.59
    • Basic EPS: 1.60
    • EBITDA: 5.249B
    • EBIT: 4.087B
    • Total Revenue: 12.872B
  • 2024-03-31:
    • Normalized Income: 3.249B
    • Net Income: 3.246B
    • Diluted EPS: 1.59
    • Basic EPS: 1.60
    • EBITDA/Operating metrics align with revenue trends around mid-12B to mid-13B. EPS Trend
  • Current (0q): 2.3108
  • +1q: 2.0531
  • 0y: 9.0012
  • +1y: 9.3556 Interpretation:
  • The quarterly EPS figure has shown a recent uptick (0q 2.31 vs prior quarter 2.05), while the year-ago annualized EPS (0y) sits around 9.00, suggesting modest quarterly volatility but a strong annual baseline when aggregated.
  • The +1y figure (~9.36) aligns with the idea of a solid forward earnings trajectory, supporting a reasonable base-case for forward valuation, given the forward P/E around 15.6x.

EPS Revisions

  • 0q: upLast7Days = 1; upLast30Days = 1; downLast30Days = 1; downLast7Days = 1
  • +1q: upLast7Days = 2; upLast30Days = 2; downLast30Days = 0; downLast7Days = 0
  • 0y: upLast7Days = 2; upLast30Days = 2; downLast30Days = 2; downLast7Days = 1
  • +1y: upLast7Days = 1; upLast30Days = 3; downLast30Days = 2; downLast7Days = 1 Interpretation:
  • Overall, revisions show a net-positive tilt in recent periods, especially for the next 12 months (+1y) with more upgrades (upLast30Days = 3) than downgrades. This supports a constructive view on earnings growth and justifies a cautious to moderate upside in the price target framework.

Technical Analysis Current Price Action and Trend

  • Price: ~131.06 USD
  • 50-Day Moving Average (latest): 124.6 (as of 2025-10-09)
  • Price vs. 50D MA: Price is above the 50D MA by roughly 6.5 points, indicating a bullish short- to intermediate-term setup.
  • RSI (14): 74.7 (near overbought, as of 2025-10-09)
  • MACD (12,26,9): MACD 2.1 vs. Signal 1.5 (bullish crossover persisted in recent moves)
  • Interpretation: The stock has exhibited bullish momentum with price above a rising 50D MA and a positive MACD. However, RSI in the high 70s suggests potential for a short-term pause or consolidation.

Key Support/Resistance (via drawn lines)

  • The chart has three horizontal levels:
    • Low Target: 120 (red line)
    • Median Target: 145 (blue line)
    • High Target: 165 (green line)
  • Implication: These lines serve as potential near-term support and resistance references depending on price action around them. The current price sits between the Median Target and the High Target, implying upside potential toward 165 if momentum sustains, while a pullback toward 120–135 would require a shift in near-term sentiment.

Analyst Consensus & Price Targets

  • Analyst Target Data: Not provided in the input (empty JSON). No explicit consensus or distribution is available in this dataset.
  • Coverage: Not specified; assume standard institutional coverage for NVS exists, but no numbers are supplied here.
  • Takeaway: Without published consensus targets in the provided data, we rely on our derived targets (120/145/165) and forward-earnings-based valuation for scenario planning.

Price Target Analysis (Short, Mid, Long-Term) Derivation note:

  • Forward earnings estimate used: approximately 9.36 CHF/USD per share (0y/ +1y EPS context in the EPS Trend data) for a 12-month view.

  • Forward P/E used: 15.56x (as given: forwardPE 15.56532).

  • Implied fair value using forward P/E = 9.36 × 15.56 ≈ 145.6 USD.

  • Our Low/Median/High levels are anchored around this framework to reflect downside, base-case, and upside scenarios.

  • Short-Term (3 months): 135 (base-case around immediate momentum, with potential near-term consolidation given RSI in the high 70s)

    • Rationale: Positive near-term earnings momentum (recent uplift in EPS and upward revisions) plus bullish MACD persists, but RSI warns of possible short-term pullback.
    • Drivers: Momentum from recent earnings, favorable macro/sector sentiment, and ongoing profitability trends.

  • Mid-Term (12 months): 145 (base-case aligned with forward earnings power and standard pharma multiple)

    • Rationale: Forward earnings around 9.36 with a ~15.6x forward multiple suggests ~145; EPS revisions have been net-positive, supporting stable growth expectations.
    • Drivers: Sustained revenue growth, margin stability, continued product-cycle resilience, potential pipeline milestones, and favorable cash deployment.

  • Long-Term (3+ years): 165 (bull-case scenario)

    • Rationale: If earnings growth accelerates (via pipeline milestones, pipeline-to-revenue realization, and potential M&A or strategic partnerships) and multiple expansion occurs, 165 represents a plausible upside target.
    • Drivers: Structural earnings growth, continued cost discipline, and potential re-rating with improved visibility on long-term earnings trajectory.

Low/Median/High Target Table (reference)

  • Low Target: 120
  • Median Target: 145
  • High Target: 165

Key Risks & Opportunities

  • Key Risks:
    • Regulatory and patent landscape: Pharma depends on a mix of drug lifecycle management; any unfavorable regulatory action or loss of exclusivity could pressure growth.
    • Pipeline execution risk: Successful commercialization of key pipeline assets is essential for mid- to long-term upside.
    • Macro and FX risk: Global pharma exposure and currency risk can affect reported earnings in USD terms.
    • RSI around overbought levels could lead to near-term consolidation or pullbacks if momentum decelerates.
  • Key Opportunities:
    • Robust margins and ROE support capital returns and potential buybacks/dividend sustainability.
    • Strong balance sheet enables strategic investments in pipeline and potential acquisitions or collaborations.
    • Forward earnings trajectory and valuation multiple relative to peers suggest room for multiple expansion if growth accelerates.

Investment Recommendation

  • Recommendation: Buy (12–24 month horizon)
  • Rationale:
    • The forward earnings framework supports an implied fair value around the mid-140s, with upside potential toward 165 under favorable earnings/pipeline outcomes.
    • The stock’s quality metrics (ROE ~32.5%, strong gross/operating margins, solid cash generation) justify a constructive stance, especially given the defensive profile (low beta, stable cash flow, and comparatively attractive dividend coverage despite the current yield being below the longer-term average).
    • Technical setup shows bullish momentum with the price well above the 50-day moving average and positive MACD, though risk factors (RSI overbought reading) imply a potential near-term pause.
  • Time Horizon: 12–24 months
  • Expected Return Potential (range):
    • Base-case target (mid-point): roughly 10–12% upside from current levels (131 → ~145)
    • Bull-case: up to ~26% upside (131 → 165)
    • Bear-case: modest downside around 8–10% (131 → ~120)
  • caveat: The price targets above are derived from forward earnings and valuation multiples, not official consensus data (which isn’t provided in the dataset). If a robust consensus emerges, re-calibration of targets would be prudent.

Technical Data Presentation (Selected Tables)

  • Selected valuation & metrics

    • Current Price: 131.06
    • Market Cap: 255.67B
    • EV: 282.11B
    • Trailing P/E: 19.13x
    • Forward P/E: 15.57x
    • P/B: 6.04x
    • ROE: 32.49%
    • ROA: 11.88%
    • Profit Margin: 24.74%
    • Gross Margin: 76.28%
    • Operating Margin: 36.83%
    • Debt/Equity: 77.61
    • Total Cash: 6.73B
    • Total Debt: 32.64B
    • Dividend Yield: 3.02%
    • Five-Year Avg Dividend Yield: 3.61%
    • Beta: 0.57

  • Technical snapshot

    • 50-Day MA (latest): 124.6
    • RSI (14): 74.7
    • MACD (12,26,9): MACD 2.1, Signal 1.5
    • Price vs. 50D MA: ~+6.4 above MA
    • Price target lines (on chart): 120 (red), 145 (blue), 165 (green)

Earnings Summary, EPS Trends, and Revisions (Key references)

  • Earnings: Latest period shows normalized income of ~4.041B and net income of ~4.041B with diluted EPS of ~2.06; revenue around 14.84B.
  • EPS Trend: Current 0q EPS ~2.31; +1q ~2.05; 0y ~9.00; +1y ~9.36 (implies a solid annualized earnings base with quarterly variability).
  • EPS Revisions: Net-positive tilt over the last 30–7 days for both 0q and +1q, with more upgrades in the +1y horizon, suggesting improving earnings visibility.

Final Observations

  • Valuation: Forward P/E of 15.6x against a robust profitability backdrop (ROE ~32%, high gross margin) supports modest upside if earnings expectations materialize.
  • Catalysts: Pipeline progress, regulatory approvals, and potential strategic collaborations or discipline in capital allocation could be near-term catalysts for upside.
  • Risk: The RSI in overbought territory calls for watching for a healthy pullback or consolidation to confirm trend sustainability.

If you’d like, I can adjust the price targets using alternative assumptions (e.g., different forward EPS scenarios, alternative forward P/Es, or currency-based translations) or tailor the price-target framework to a specific time horizon or risk tolerance.

Chart is loading...